ChenGuang Biotech Group Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Qingguo Lu

Chief executive officer

CN¥4.0m

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	18.4%
Management average tenure	no data
Board average tenure	less than a year

Recent management updates

Recent updates

Impressive Earnings May Not Tell The Whole Story For ChenGuang Biotech Group (SZSE:300138)

Apr 25

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) Just Reported, And Analysts Assigned A CN¥17.66 Price Target

Apr 21

CEO

Qingguo Lu (64 yo)

no data

Tenure

CN¥4,020,900

Compensation

Mr. Qingguo Lu is Chairman & GM of ChenGuang Biotech Group Co., Ltd.

Board Members

Name	Position	Tenure	Compensation	Ownership
Qingguo Lu	Chairman & GM	no data	CN¥4.02m	18.43% CN¥ 892.8m
Jing Zhou	CFO, Secretary of the Board & Director	5.1yrs	CN¥539.80k	1.55% CN¥ 75.2m
Tao Zhao	Employee Representative Supervisor	no data	no data	0.0099% CN¥ 481.5k
Ying Lu	Non-Independent Director	less than a year	no data	no data
Wei Gao	Supervisory Board Chairman	no data	no data	0.014% CN¥ 674.3k
Shaohua Wang	Non Employee Representative Supervisor	no data	no data	no data
Xiaofeng Dai	Independent Director	less than a year	no data	no data
Hong Niu	Independent Director	less than a year	no data	no data
Liangqiu Li	Independent Director	less than a year	no data	no data

1.0yrs

Average Tenure

43yo

Average Age

Experienced Board: 300138's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.

ChenGuang Biotech Group Management

Management criteria checks 0/4

Key information

Recent management updates

ChenGuang Biotech Group Co., Ltd., Annual General Meeting, May 09, 2024

Chenguang Biotech Group Co., Ltd. Announces Management Appointment

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Price target decreased by 7.3% to CN¥17.31

Impressive Earnings May Not Tell The Whole Story For ChenGuang Biotech Group (SZSE:300138)

Consensus EPS estimates fall by 15%, revenue upgraded

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) Just Reported, And Analysts Assigned A CN¥17.66 Price Target

ChenGuang Biotech Group Co., Ltd., Annual General Meeting, May 09, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 16%

ChenGuang Biotech Group Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Full year 2023 earnings released: EPS: CN¥0.91 (vs CN¥0.81 in FY 2022)

ChenGuang Biotech Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 18, 2024

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) commences an Equity Buyback Plan for CNY 100 million worth of its shares, under the authorization approved on November 17, 2023.

Price target decreased by 8.0% to CN¥20.43

Third quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.18 in 3Q 2022)

ChenGuang Biotech Group Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

ChenGuang Biotech Group Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

Chenguang Biotech Group Co., Ltd. Announces Management Appointment

ChenGuang Biotech Group Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 17 May 2023

First quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.20 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.82 (vs CN¥0.67 in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.12 in 3Q 2021)

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Chenguang Biotech Group Co., Ltd. Announces 2021 Final Cash Dividend Proposal on A Shares, Payable on 1 June 2022

Consensus revenue estimates increase by 11%

Insufficient new directors

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chenguang Biotech Group Co., Ltd. Approves Cash Dividend

Full year 2021 earnings: EPS and revenues exceed analyst expectations

ChenGuang Biotech Group Co., Ltd. Announces Final Dividend For the Year 2021

Price target increased to CN¥20.80

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.11 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.19 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.12 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.54 (vs CN¥0.38 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.54 (vs CN¥0.38 in FY 2019)

Revenue and earnings beat expectations

ChenGuang Biotech Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day low: CN¥15.29

Investor sentiment deteriorated over the past week

New 90-day high: CN¥19.53

Market bids up stock over the past week

New 90-day high: CN¥18.18

Third quarter earnings released

ChenGuang Biotech Group Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) agreed to acquire an additional 24.83% stake in Xinjiang Tianjiao Hongan Agricultural Technology Co., Ltd. from Xinjiang Longping Gaoke Hong'an Seed Industry Co., Ltd. for CNY 20 million.

Earnings released

ChenGuang Biotech Group Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥16.99

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) cancelled the acquisition of 10% stake in Tengchong Kang’enpu Biological Materials Co., Ltd. from Zhu Jingbo, Chen Xin and Zhang Jiaqi.

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age